The EMBO Journal7d
Nuclear PD-L1 triggers tumour-associated inflammation upon DNA damage
PD-L1 not only responds to the cGAS-STING pathway upon DNA damage, but also regulates cGAS-STING to induce inflammation. This ...
New AI tool uses routine blood tests to predict immunotherapy response for many cancers
Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will ...
pharmaphorum1d
Merck gets FDA okay for Keytruda as liver cancer therapy
Other companies with checkpoint inhibitors on the market also have HCC in its sights, including Merck KGaA/Pfizer whose Bavencio (avelumab) PD-L1 inhibitor is in phase II testing in this indication.
Managed Healthcare Executive1d
AI Model Predicts Immunotherapy Response in Advanced Lung Cancer Patients
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
precisionmedicineonline7d
BeiGene Nabs FDA Approval for Tevimbra With Chemo in First-Line PD-L1-Positive Gastric Cancer
Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.
Businessworld12d
who won yesterday test match
who won yesterday test match The commercialization of PD-L1 products is just around the corner. Alphamab Oncology's performance on the Hong Kong Stock Exchange boosts market confidence The number of ...